Delivery Order SPE2DB20D3103-SPE2DB25FP8W6
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Eliquis 5 mg tablets (60-count packages) with a ceiling value of $18,978.90. This non-set-aside competitive award is scheduled for completion by August 8, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Eliquis 5 mg tablets (60-count packages) valued at $25,897.33. This non-set-aside, competitively awarded contract represents a firm fixed-price delivery order with an ultimate completion date of July 25, 2025. The award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical supply...
- The Defense Logistics Agency awarded a $12.5K delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Eliquis 5 mg tablets (60-count units). This non-set-aside, firm fixed price delivery order is set to complete by August 13, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier within the federal healthcare procurement...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Eliquis 5 mg tablets (60-count) valued at $4,327.68. This is a firm fixed-price delivery order with no set-aside designation, reflecting AmerisourceBergen's capability to compete successfully in open federal procurement. The contract completion date is August 1, 2025, and the place of performance is the company's corporate office in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $3,967.45 to AmerisourceBergen Drug Corp for 60 tablets of Eliquis 5 mg on August 18, 2025, with an ultimate completion date of August 19, 2025. The contract carries firm fixed pricing with no set-aside designation, indicating competitive award under open procurement. Performance will be fulfilled from the vendor's corporate office located in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $5,084.04 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Eliquis 5 mg tablets in a 60-count package. This competitively awarded, non-set-aside contract is scheduled for completion by July 25, 2025, with performance to be fulfilled at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract action under AmerisourceBergen's larger pharmaceutical...
- The Defense Logistics Agency awarded a $11,794.32 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Eliquis 5 mg tablets (60-count units). This is a firm fixed price, competitively awarded contract with no set-aside designation, requiring completion by July 31, 2025. AmerisourceBergen will fulfill this order from its Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical distributor serving...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,789.52 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count units) on August 27, 2025, with an ultimate completion date of August 28, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December...
- The Defense Logistics Agency awarded a delivery order valued at $14,404.90 to AmerisourceBergen Drug Corp for 60-tablet units of Eliquis 5 mg on July 22, 2025, with completion scheduled for July 23, 2025. This non-competitive, firm fixed-price delivery order was issued under a child contract arrangement and represents a pharmaceutical supply transaction for federal medical procurement. The award was performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Eliquis 5 mg tablets (60-count units) with a contract ceiling value of $7,458.91. This competitively awarded, firm fixed-price delivery order is part of AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The delivery order is scheduled for completion by August 11, 2025, with...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP8W6Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $8,535.48 to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Eliquis 5 mg tablets in quantities of 60. The contract carries a firm fixed price structure with no set-aside designation, indicating competitive award. Performance will be executed at the vendor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 15, 2025. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical federal medical procurement vendor through its comprehensive IDC vehicle that enables supply of brand-name and generic medications, vaccines, and specialized medical commodities across multiple therapeutic domains to support military healthcare systems. The company's federal contract portfolio demonstrates consistent capability to meet DLA requirements through open competition, with delivery orders ranging substantially in value. The current award for Eliquis, an anticoagulant medication, exemplifies the company's role in supplying essential pharmaceutical products to support Defense Health Agency operations and other federal healthcare entities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.5k | 8/14/25 |